Mechanism of Action of Empagliflozin and Dapagliflozin
Both empagliflozin and dapagliflozin are SGLT2 inhibitors that work by blocking sodium-glucose cotransporter 2 in the proximal renal tubules, preventing reabsorption of filtered glucose and causing urinary glucose excretion of approximately 60-80 grams per day. 1, 2
Primary Renal Mechanism
SGLT2 protein location and function:
- SGLT2 is expressed predominantly in the proximal tubule of the kidney 3
- Under normal conditions, SGLT2 is responsible for reabsorbing up to 90% of filtered glucose from the glomerular filtrate back into circulation 3, 1
- In chronic hyperglycemia, SGLT2 protein expression becomes upregulated, increasing maximum glucose transport capacity 3
Direct inhibition effects:
- By inhibiting SGLT2, both drugs reduce renal glucose reabsorption and lower the renal threshold for glucose 1, 2
- This increases urinary glucose excretion—empagliflozin produces approximately 64-78 grams/day of glucose excretion, while dapagliflozin produces approximately 70 grams/day 3, 2
- The mechanism is completely insulin-independent, making these drugs effective regardless of pancreatic β-cell function 4
Secondary Hemodynamic and Cardiovascular Mechanisms
Beyond glucose lowering, both drugs affect sodium handling:
- SGLT2 inhibition reduces sodium reabsorption in the proximal tubule 2
- Increased sodium delivery to the distal tubule triggers tubuloglomerular feedback, causing afferent arteriole constriction 3
- This reduces intraglomerular pressure, providing renal protection 3
Cardiovascular effects include: 5, 2
- Osmotic diuresis leading to reduced preload and afterload on the heart
- Decreased intravascular volume (initial urine volume increase of ~135-341 mL/day) 1
- Downregulation of sympathetic nervous system activity
- Improved myocardial energetics and cardiac fuel metabolism 6
- Blood pressure reduction through natriuresis
Pharmacological Distinctions
While both drugs share the core SGLT2 inhibition mechanism, subtle differences exist:
Selectivity: Both empagliflozin and dapagliflozin are highly selective SGLT2 inhibitors and much weaker SGLT1 inhibitors compared to canagliflozin 7. Molecular docking studies suggest empagliflozin may show slightly stronger binding interactions with SGLT1/2 targets 8, though clinical significance remains unclear.
Pharmacokinetics:
- Empagliflozin: Peak concentration at 1.5 hours, terminal half-life allows once-daily dosing, 86.2% protein bound 1
- Dapagliflozin: Peak concentration at 2 hours, half-life approximately 12.9 hours, 91% protein bound, 78% oral bioavailability 2, 7
Metabolism:
- Empagliflozin: Primarily glucuronide conjugation, minimal CYP involvement 1
- Dapagliflozin: Primarily UGT1A9-mediated metabolism to inactive 3-O-glucuronide (61% of dose), minor CYP pathway 2, 7
Clinical Implications of Mechanism
The insulin-independent mechanism allows:
- Use across all stages of type 2 diabetes, including advanced β-cell dysfunction 4
- Combination with other antidiabetic agents without additive hypoglycemia risk 4
- Efficacy maintained even in moderate renal impairment (though glucose-lowering effect diminishes as eGFR declines) 1
Common pitfall: The mechanism becomes less effective as renal function declines because there is less filtered glucose to block reabsorption. Both drugs are not expected to provide glycemic benefit in severe renal impairment (eGFR <30 mL/min/1.73 m²), though cardiovascular and renal benefits may persist 1, 2.
The hemodynamic mechanism explains:
- Rapid cardiovascular mortality benefit seen in EMPA-REG OUTCOME (within months, too fast for antiatherosclerotic effects) 5, 6
- Consistent heart failure hospitalization reduction across trials regardless of diabetes status 5
- Initial eGFR dip of ~5 mL/min within 1-2 weeks (hemodynamic effect, not kidney injury) that subsequently stabilizes 3